Monthly Archives: February 2020

//February

NHSE&I COVID-19 guidance for community pharmacy published

NHS England and NHS Improvement (NHSE&I) have this afternoon (27th February 2020) published new Coronavirus (COVID-19) guidance for primary care teams. This includes a specific document for community pharmacy teams, which takes the guidance already available on the GOV.UK website, but contextualises it for the community pharmacy environment. Novel coronavirus (COVID-19) standard operating procedure –...

By |February 27th, 2020|Lexpos News|Comments Off on NHSE&I COVID-19 guidance for community pharmacy published

NHSE&I COVID-19 guidance for community pharmacy published

NHS England and NHS Improvement (NHSE&I) have this afternoon (27th February 2020) published new Coronavirus (COVID-19) guidance for primary care teams. This includes a specific document for community pharmacy teams, which takes the guidance already available on the GOV.UK website, but contextualises it for the community pharmacy environment. Novel coronavirus (COVID-19) standard operating procedure –...

By |February 27th, 2020|Lexpos News|Comments Off on NHSE&I COVID-19 guidance for community pharmacy published

Class 4 Medicines Defect Information: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd)

Drug alert number: EL(20)/A12 Date issued: 27 February 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd) G.L. Pharma GmbH T/A Healthcare Pharma Ltd has informed the MHRA that the Patient Information...

By |February 27th, 2020|Lexpos News|Comments Off on Class 4 Medicines Defect Information: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd)

Class 4 Medicines Defect Information: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd)

  Drug alert number: EL(20)/A12 Date issued: 27 February 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd) G.L. Pharma GmbH T/A Healthcare Pharma Ltd has informed the MHRA that the Patient...

By |February 27th, 2020|Lexpos News|Comments Off on Class 4 Medicines Defect Information: Oxylan Prolonged-release tablets (oxycodone hydrochloride) (G.L. Pharma GmbH T/A Healthcare Pharma Ltd)

Updated – Supply Disruption Alert – Diamorphine Hydrochloride powder for reconstitution and injection 5mg and 10mg ampoules

Updated 25/03/2020 MHRA has today asked that healthcare professionals make permanent the recommended actions originally communicated below. Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Diamorphine Hydrochloride Powder for Reconstitution and Injection 5mg and 10mg ampoules. There are two suppliers of diamorphine hydrochloride 5mg and 10mg in the...

By |February 26th, 2020|Lexpos News|Comments Off on Updated – Supply Disruption Alert – Diamorphine Hydrochloride powder for reconstitution and injection 5mg and 10mg ampoules